Hematology/Oncology

Top Story

European Society for Radiotherapy and Oncology honors Karmanos Cancer Institute professor

European Society for Radiotherapy and Oncology honors Karmanos Cancer Institute professor
June 28, 2017

The European Society for Radiotherapy and Oncology will honor Michael C. Joiner, PhD, with the 2018 ESTRO Lifetime Achievement Award at the organization’s annual conference next spring in Barcelona.

The award recognizes Joiner — professor of radiation oncology at Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine — for his contribution to ESTRO activities.

Family history of prostate cancer should not determine active surveillance eligibility

June 28, 2017
Family history did not appear associated with increased risk for aggressive disease among certain men with early prostate cancer, according to study results published in…
Meeting NewsVideo

VIDEO: Novel agent improves response rate in urothelial cancer

June 27, 2017
CHICAGO – A novel antibody drug conjugate demonstrated promising activity among patients with metastatic urothelial cancer, according to a study presented at the…

‘Lives of our patients are at stake’ as concerns about Senate health care bill mount

June 27, 2017
The cost savings that would be realized under the Senate’s proposed health care bill would have a dramatic negative effect on the quality of health care offered in…
In the Journals

Mortality risk likely to be higher among uninsured patients

June 27, 2017
With the Congressional Budget Office report indicating that 22 million Americans will lose insurance coverage by 2026 under
More News Headlines »
CME

Diagnostic and Therapeutic Challenges in Von Willebrand Disease

This activity is supported by an educational grant from Shire.

With the significant variability in the subtypes and clinical manifestations of von Willebrand disease (VWD), diagnosis…
More »
Video
Meeting News

VIDEO: Role of adjuvant chemotherapy in nasopharynx cancer remains uncertain

June 19, 2017
More »
Featured

CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement